5

10



-23-

Abstract of the Disclosure

The use of low doses of IFN-gamma in the treatment of interferonsensitive diseases is described. The IFN-gamma can be administered orally,
preferably buccally or sublingually, or parenterally in low doses to activate monocyte,
neutrophil, or B cell function, to decrease acute inflammation, or to treat cancer,
bacterial or fungal diseases, or fibrosis in a patient suffering from such disease states.
Pharmaceutical formulations containing low doses of IFN-gamma in combination
with a pharmaceutical acceptable carrier and suitable for oral administration are also
described.